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Abstract
Purpose The purpose of the study is to evaluate the effect of
renal impairment (RI) and end-stage renal disease (ESRD) on
the pharmacokinetics (PK) of isavuconazole and the inactive
cleavage product, BAL8728.
Methods A single intravenous dose of the prodrug
isavuconazonium sulfate (372 mg, equivalent to 200 mg
isavuconazole and 75 mg of BAL8728 cleavage product)
was administered to healthy controls (parts 1 and 2) and par-
ticipants with mild, moderate, or severe RI (part 2) or ESRD
(part 1); ESRD participants received two doses of 200 mg
isavuconazole, 1 h post-dialysis (day 1) and prior to dialysis
(day 15). Plasma PK parameters for isavuconazole included
maximum concentration (Cmax), area under the concentra-
tion–time curve (AUC) from time of dose to 72 h (AUC72),
AUC extrapolated to infinity (AUC∞), AUC to last measur-
able concentration (AUClast), half-life (t½ h), volume of distri-
bution (Vz), and total clearance (CL), for the healthy control
group versus those with mild, moderate, or severe RI or
ESRD.
Results IsavuconazoleCmax values were 4% higher in mild RI
and 7, 14, and 21% lower in participants with moderate RI,
severe RI, or ESRD versus the healthy control group,
respectively. When hemodialysis occurred post-dose (day
15), participants with ESRD had a 30% increase in AUC72
for isavuconazole in parallel with reduction of extracellular
volume induced by dialysis. Exposure (AUC∞ and AUClast)
was not significantly different for participants with mild, moder-
ate, or severe RI versus healthy controls although there was
considerable variability. The t1/2 (day 1) was 125.5 ± 63.6 h
(healthy control group), 204.5 ± 82.6 h (ESRD group) in part
1, and 140.5 ± 77.7 h (healthy control group), 117.0 ± 66.2 h
(mild RI), 158.5 ± 56.4 h (moderate RI), and 145.8 ± 65.8 L/h
(severe RI) in part 2. CL was 2.4 ± 0.8 L/h (healthy control
group) and 2.9 ± 1.3 L/h (ESRD group) in part 1 and 2.4 ± 1.2
L/h (healthy control group), 2.5 ± 1.0 L/h (mild RI), 2.2 ± 0.8 L/h
(moderate RI), and 2.4 ± 0.8 L/h (severe RI) in part 2. TheVz was
382.6 ± 150.6 L in the healthy control group and 735.6 ± 277.3 L
in ESRD patients on day 1 in part 1 of the study. In part 2 of the
study, Vz was 410.8 ± 89.7 L in the healthy control group,
341.6 ± 72.3 L in mild RI, 509.1 ± 262.2 L in moderate RI,
and 439.4 L in severe RI.
Conclusions Based on the findings of this study, dose adjust-
ments of isavuconazole are unlikely to be required in individuals
with RI or in those with ESRD who receive hemodialysis.
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Introduction
Invasive fungal diseases (IFD), predominantly aspergillosis, are a
prevalent cause of morbidity and mortality in immunocompro-
mised patients, such as those with hematological malignancies or
those undergoing transplantation [1–4]. Renal impairment (RI) is
an independent risk factor for mortality in both hematopoietic
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stem cell transplant and solid organ transplant patients with in-
vasive aspergillosis (IA) [5]. In intensive care units, 43% of
patients with IA infections experience acute renal failure,
which contributes to the mortality associated with IA [6].
The renal excretion of drugs and/or their metabolites may
be hindered in patients with RI, and this could lead to an
excessive accumulation of the drug in the body [7].
Conversely, hemodialysis may result in removal of some
drugs, and thereby, additional doses may be required to
prevent underdosing [8]. Triazole antifungal agents are
pivotal in the treatment of IA [9]; however, their use
may be restr icted in pat ients with RI [10, 11].
Voriconazole and posaconazole may have restricted use
in patients with moderate-to-severe RI due to the accumu-
lation of the vehicle cyclodextrin used in their intravenous
(IV) formulations [10–12]. Caution is also recommended
for the use of itraconazole in patients with RI due to
limited data on the use of this drug in this patient popu-
lation [13]. Therefore, there is a requirement for potent
antifungal agents that are efficacious and well tolerated
to combat IFD in patients with RI.
Isavuconazonium sulfate is a water-soluble prodrug of
the novel, broad-spectrum, triazole antifungal agent
isavuconazole, which was developed to facilitate IV ad-
ministration without the need for nephrotoxic excipients
[14, 15]. Isavuconazonium sulfate is rapidly converted in
plasma to the active triazole isavuconazole and the inac-
tive cleavage product BAL8728. The per-oral (PO) cap-
sules and cyclodextrin-free IV formulations of the
prodrug are approved for the primary treatment of adults
with IA and invasive mucormycosis by the US Food and
Drug Administration (FDA) [16]. Isavuconazole is also
approved by the European Medicines Agency (EMA)
for the treatment of IA and treatment of invasive
mucormycosis when amphotericin B is inappropriate
[17].
A formal renal study using the final formulation,
isavuconazonium sulfate, was conducted in accordance with
the FDA and the EMA guidance on the evaluation of the
pharmacokinetics (PK) of medicines in patients with impaired
renal function [18, 19]. The objective of this study was to
evaluate the effect of RI (mild, moderate, or severe) and
end-stage renal disease (ESRD) on the PK of isavuconazole




This was a phase I, open-label, single-dose parallel group
study in male and female participants conducted in two
parts (ClinicalTrials.gov NCT01555866 covering parts 1
and 2). Part 1 was a single-center study of isavuconazole
administered to healthy participants with renal function in
the normal range (referred to as the healthy control group)
and those with ESRD requiring dialysis. Part 2 was a
multi-center study of isavuconazole administered to a
healthy control group and those with mild, moderate, or
severe RI.
Both parts of the study were conducted in accordance with
the Declaration of Helsinki and the International Conference
on Harmonisation Guidelines for Good Clinical Practice. For
all sites, approval of the protocol (9766-CL-0018) was obtain-
ed from the governmental authorities and Institutional Review
Board(s).
Eligibility
Male and female participants aged 18–65 years, weighing
≥45 kg, and with a body mass index of 18–35 kg/m2
were enrolled. At screening, RI was based on the
Cockcroft–Gault (CG) formula and adjusted for body sur-
face area (BSA), then grouped as healthy control group
(creatinine clearance (CLcr) >80 mL/min/1.73 m
2), partic-
ipan ts wi th ESRD and requi r ing hemodia lys i s
(CLcr < 15 mL/min/1.73 m
2), and participants with RI:
mild (CLcr 50–80 mL/min/1.73 m
2), moderate (CLcr 30–
<50 mL/min/1.73 m2), and severe CLcr (<30 mL/min/
1.73 m2). Participants were selected by age, sex, weight,
and smoking status so that the ranges were similar be-
tween the healthy control group and each of the groups
with RI.
Assessments
Each participant in part 1 and part 2 of the study received a
single 1-h IV infusion of isavuconazonium sulfate 372 mg
(equivalent to 200 mg isavuconazole) on day 1 (approximate-
ly 1 h after completion of their routine hemodialysis procedure
in participants with ESRD). Participants with ESRD in part 1
of the study received an additional dose just prior to dialysis
on day 15.
Blood samples for isavuconazole and BAL8728 plasma
concentrations were collected pre-dose to 72 h post-dose
on days 1 and 15 for ESRD participants and pre-dose to
72 h post-dose on day 1 for the healthy control group and
RI participants. Single blood samples were taken from
ESRD and RI participants on days 6, 8, 11, 13, and 15.
During dialysis, samples were collected simultaneously at
the inlet and outlet sides of the dialyzer as well as from
the dialysate. For all participants, an additional blood
sample was obtained at 4 h post-dose on day 1 for anal-
ysis of isavuconazole fraction unbound (fu).
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In participants who produced urine, samples for the
bioanalysis of isavuconazole and BAL8728 were col-
lected up to 72 h post-dose on day 1. Renal function
was assessed using the CG method adjusted for BSA




¼ 140−age yearsð Þ½   actual weight kgð Þ  0:85 for females  1:73
72 Scr mg=dLð Þ  BSA
where Scr is serum creatinine.
Estimated glomerular filtration rate (eGFR) using the
abbreviated Modification of Diet in Renal Disease
(MDRD) formula was calculated using the following
formula:
eGFR−MDRD mL=min=1:73 m2
¼ 175 Scr−1:154  age−0:203  0:742 if femaleð Þ
 1:212 if African Americanð Þ
Pharmacokinetic assessments
Due to the extensive protein binding of isavuconazole to
plasma proteins, the PK parameters reported in this
study were based on total isavuconazole concentrations
in plasma. Plasma PK sampling time points included
pre-dose (prior to start of infusion), upon completion
of infusion (obtained 1 min prior to end of infusion),
1.5, 2, 3, 4, 5, 6, 8, 12, 24 (day 2), 36 (day 2), 48 (day
3), 72 (day 4), 120 (day 6), 168 (day 8), 240 (day 11),
288 (day 13), 336 (day 15) h after the start of infusion.
The primary plasma PK parameters for isavuconazole
were area under the concentration–time curve (AUC)
from time of dosing to 72 h (AUC72) and maximum
concentration (Cmax) for the healthy control group com-
pared with participants with ESRD, AUC from time of
dosing extrapolated to infinity (AUC∞), AUC from time
of dosing to last measurable plasma concentration
(AUClast), and Cmax for the healthy control group com-
pared with participants with mild, moderate, or severe
RI. Additional PK parameters for isavuconazole includ-
ed time to reach Cmax (tmax), total clearance (CL), half-
life (t½), and volume of distribution (Vz). PK parameters
for BAL8728 included: healthy, ESRD, and RI partici-
pants (day 1): AUC∞, AUC72, AUClast, Cmax, tmax, t1/2,
Vz, and CL: ESRD participants (day 15): AUC72, Cmax,
and tmax.
Urine was collected for all able subjects over the
following time intervals: day 1 pre-dose (−2 to 0) 0–6,
6–12, 12–24, 24–48, and 48–72 h after start of infusion.
PK parameters included the amount and percentage of
drug excreted unchanged in the urine (Aelast/Ae72, for
the dialysis comparisons) for all participants and renal
clearance (CLR calculated as Aelast/AUClast) at day 1 for
the healthy control group and participants with mild,
moderate, or severe RI; dialysis clearance (CLD) at
day 15 was also assessed for participants with ESRD.
Plasma PK parameters were calculated using WinNonlin®
version 5.2 or higher (Certara, Princeton, NJ, USA).
Safety assessments
Treatment-emergent adverse events (TEAEs; defined as
adverse events that started any time after the first dose
of study drug was administered through the follow-up
visit) were assessed for all participants. The number and
percentage of participants with TEAEs were summarized
for each renal function group by system organ class.
Statistical analysis
A sample size of 16 participants (8 per group) in part 1
of the study and 32 participants (8 per group) in part 2
of the study was determined based on the precedent set
by other PK studies similar in design. No formal sample
size calculation was performed.
The PK analyses used two approaches: One ap-
proach compared PK between each renal impaired
group (CG method CLcr), and a second approach com-
pared the relationship between PK and eGFR (MDRD
method). Descriptive statistics (number of participants,
mean, and standard deviation, minimum, median, and
maximum) were used to summarize continuous vari-
ables. Descriptive statistics used for categorical vari-
ables consisted of frequency and percentage of partic-
ipants in each category. In addition, for PK parame-
ters, geometric mean and coefficient of variation were
also determined.
To a s s e s s t h e e f f e c t o f R I on th e PK o f
isavuconazole and BAL8728, an analysis of covariance
(ANCOVA) was performed on natural log-transformed
AUC∞, AUClast, and Cmax with renal function group
(mild, moderate, or severe RI and healthy control
group) as a fixed effect and age, sex, and current
smoking status as covariates. The effect of time of
dialysis relative to dosing on the PK of isavuconazole
and BAL8728 was assessed using ANCOVA on the
natural log-transformed AUC72 and Cmax between day
1 and day 15 (calculated using pre-dialysis access line
concentrations), while subjects were on dialysis from
the ESRD group with the visit as a fixed effect (day 1
and day 15), the subject as a random effect, and
weight on day 1 and day 15 as a covariate. The 90%
confidence intervals (CIs) around the geometric least
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square mean (LSM) ratios (day 15/day 1) of AUC72
and Cmax were constructed.
Covariates were assessed at the 0.1 significance level and
removed from the model if insignificant. The 90% CIs around
the geometric LSM ratios (severe/healthy control group,
moderate/healthy control group, and mild/healthy control
group) of AUC∞, AUClast, and Cmax were constructed. No
effect of RI on PK was declared if the corresponding CIs for
the ratio fell completely within the interval (70%, 143%) for
all three parameters of isavuconazole.
Safety data were analyzed using descriptive statistics. All
statistical analyses were performed using SAS® version 9.1 or
higher (Statistical Analysis Software, Cary, NC, USA).
Results
Patient characteristics
A total of 20 participants were enrolled, and 19 completed part
1 of the study; 29 participants were enrolled and completed
part 2 of the study (Table 1). Only five participants were en-
rolled in the severe RI group due to slow recruitment.
Dialysis and PK of isavuconazole and BAL8728
Mean plasma concentration–time profiles for isavuconazole in
participants with ESRD compared with the healthy control
group are shown in Fig. 1. More than 99.9% of isavuconazole
was bound to protein in samples from all treatment groups. On
day 1, when isavuconazonium sulfate was administered as a
1-h IV infusion post-hemodialysis in ESRD participants, there
was a 34% decrease in AUC72 of isavuconazole and a 21%
decrease in Cmax compared with the healthy control group
dosed under similar conditions (Table 2). BAL8728 Cmax
values were 2% lower in participants with ESRD, compared
with the healthy control group. The AUC72 for isavuconazole
increased by 30% and the AUC72 for BAL8728 decreased by
22% (Table 2) with dosing of isavuconazole prior to dialysis
in participants with ESRD. The day 15 result was similar to
the AUC72 results obtained for the healthy control group on
day 1 (Table 3). The mean t1/2 of total isavuconazole was
approximately 1.6-fold longer in participants with ESRD ver-
sus the healthy control group (Table 3). Less than 1% of the
administered isavuconazole was recovered in dialysate fluid,
consistent with the low dialysis clearance (CLD) of 292 mL/h.
Isavuconazole and BAL8728 PK in renal impairment
There were no consistent changes in t1/2 of isavuconazole or
BAL8728 plasma concentrations observed in participants
with mild-to-severe RI versus healthy control group
(Table 4; Supplementary Table S1). Compared with the
healthy control group, plasma BAL8728 AUC72 for subjects
with ESRD was 10% higher, whereas the plasma AUC∞ in
mild, moderate, or severe RI groups were 29, 4, and 24%
higher, respectively. Ae % and CLR for both isavuconazole
and BAL8728 decreased with increasing RI (mild to severe).
BAL8728 Cmax values in participants with mild and severe RI
were 16 and 11% higher, respectively, and 3% lower in par-
ticipants with moderate RI.
Table 1 Demographics and characteristics of participants
Study part 1 Study part 2
Healthy control











Age [years], median (range) 48 (19–64) 52 (20–64) 51 (34–57) 63 (51–65) 56 (34–61) 59 (50–62)
Males, n (%) 5 (55.6) 5 (45.5) 5 (62.5) 5 (62.5) 3 (37.5) 5 (100)
Race, n (%)
White 8 (88.9) 1 (9.1) 6 (75.0) 8 (100) 4 (50.0) 3 (60.0)
Black or African American 0 10 (90.9) 2 (25.0) 0 3 (37.5) 2 (40.0)
Other 1 (11.1) 0 0 0 1 (12.5) 0
Ethnicity, n (%)
Not Hispanic or Latino 9 (100) 11 (100) 4 (50.0) 3 (37.5) 5 (62.5) 3 (60.0)
eGFR-CG, mean ± SDa













CG Cockcroft–Gault method, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease, MDRD modification of diet in renal disease,
RI renal impairment, SD standard deviation
a eGFR-CG (mL/min/1.73 m2 ) × Body surface area/1.73
b eGFR-MDRD (mL/min/1.73 m2 )
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There was no significant relationship between total plasma
isavuconazole PK parameters (Cmax and CL) with continuous
markers of renal function CLcr and eGFR using either the CG
or the abbreviated MDRD formula (Fig. 2, Supplementary
Fig. S1). No correlation was identified between BAL8728 PK
parameters and markers of renal function (data not shown).
Fig. 1 Mean (standard deviation
[SD]) plasma concentration–time
profiles for isavuconazole in a
healthy control group (day 1)
versus participants with end-stage
renal disease on both day 1 and
day 15 and b for participants with
mild, moderate, and severe RI
versus the healthy control group
Table 2 Geometric LSM ratios
for isavuconazole and BAL8728
in patients with ESRD versus
healthy controls and for ESRD at
day 15 versus day 1






















AUC72 ESRD day 15/ESRD day 1 78.2 68.6–89.0
AUC72 area under the concentration curve at 72 h, CI confidence intervals,Cmaxmaximum plasma concentration,
ESRD end-stage renal disease, LSM least square mean
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Urinary excretion
Isavuconazole urinary clearance decreased in parallel with a
decrease in renal function (Supplementary Table S2). The
amount of isavuconazole excreted unchanged in urine sam-
ples was 0.07% of the total dose in patients with severe RI
compared with 0.44% in the healthy control group. The small
volume of the dialysis clearance in participants with ESRD
was consistent with the highly albumin-bound nature of
isavuconazole (Supplementary Table S2). BAL8728 was not
detected in dialysate samples.
Safety
Most TEAEs were considered mild. No participant experi-
enced a TEAE that was considered severe, and no deaths
were reported during the course of the study. However, one
healthy participant in part 1 of the study experienced a TEAE
Table 3 Isavuconazole and BAL8728 pharmacokinetic parameters for participants with ESRD and healthy control group
Parameter Isavuconazole BAL8728
Healthy control











AUC72, mg*h/L 36.9 ± 9.5 25.1 ± 10.0 32.3 ± 15.4 1.2 ± 0.4 1.3 ± 0.3 0.9 ± 0.2
Cmax, mg/L 4.6 ± 1.1 3.7 ± 1.3 3.7 ± 0.8 0.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.2
AUC∞, mg*h/L 94.7 ± 32.3 95.7 ± 78.6 – 1.2 ± 0.4 1.3 ± 0.3 –
AUClast, mg*h/L 77.9 ± 22.1 62.0 ± 40.2 – 1.1 ± 0.3 1.2 ± 0.3 –
tmax, h 1.0 (1.0–1.1) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.1) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
t½, h 125.5 ± 63.3 204.5 ± 82.6 – 1.3 ± 0.1 1.5 ± 0.3 –
Vz, L 386.2 ± 150.5 735.6 ± 277.3 – 133.3 ± 35.2 144.3 ± 64.3 –
CL, L/h 2.4 ± 0.8 2.9 ± 1.3 – 70.5 ± 23.0 64.5 ± 23.9 –
Aelast, % 0.5 ± 0.2 – – – – –
CLR, mL/h 12.5 ± 5.5 – – – – –
CLD, mL/h – 291.7 ± 87.4 – – – –
All PK data expressed as mean ± standard deviation, except tmax, which is expressed as median (range)
Aelast cumulative amount of unchanged isavuconazole excreted in the urine, AUC area under the concentration–time curve, AUC72 AUC from time of
dosing until 72 h, AUC∞ AUC extrapolated to infinity, AUClast AUC to last measurable plasma concentration, Cmax maximum concentration of
isavuconazole, CL total clearance of isavuconazole, CLD dialysis clearance of isavuconazole, CLR renal clearance of isavuconazole from plasma,
ESRD end-stage renal disease, tmax time to reach maximum concentration, t½ half-life of isavuconazole
a One participant discontinued on day 1
b Pharmacokinetic results for three participants with ESRD were unavailable due to a handling error during sample collection resulting in the contam-
ination of Cmax values
Table 4 Isavuconazole
pharmacokinetic parameters for
day 1 for healthy participants
compared with individuals with
renal impairment
Parameter Healthy control







AUC∞, mg*h/L 98.8 ± 50.5 96.2 ± 46.9 97.2 ± 26.3 98.8 ± 53.9
AUClast, mg*h/L 75.8 ± 22.9 77.0 ± 22.8 74.0 ± 20.1 73.6 ± 19.9
tmax, h 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
t½, h 140.5 ± 77.7 117.0 ± 66.2 158.5 ± 56.4 145.8 ± 65.8
Cmax, mg/L 4.4 ± 0.7 3.9 ± 1.1 4.1 ± 1.4 3.4 ± 0.9
CL, L/h 2.4 ± 1.2 2.5 ± 1.0 2.2 ± 0.8 2.4 ± 0.8
Aelast, % 0.4 ± 0.2 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.03
CLR, mL/h 14.0 ± 13.3 6.8 ± 4.3 3.4 ± 2.7 2.0 ± 0.9
Vz, L 410.8 ± 89.7 341.6 ± 72.3 509.1 ± 262.2 439.4 ± 65.4
All data are expressed as mean ± standard deviation, except tmax which is expressed as median (range)
Aelast cumulative amount of unchanged isavuconazole excreted in the urine, AUC area under the concentration–
time curve, AUC72AUC from time of dosing until 72 h, AUC∞AUC extrapolated to infinity, AUClastAUC to last
measurable plasma concentration,CL total clearance of isavuconazole,CLR renal clearance of isavuconazole from
plasma, RI renal impairment, tmax time to reach maximum concentration, t½ half-life of isavuconazole, Vz volume
of distribution
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(chest discomfort) during IV administration of isavuconazole
that was considered related to the study drug and led to dis-
continuation from the study (Table 5).
Discussion
This study showed that there was no significant impact of
renal function measured by either CLcr or eGFR on
isavuconazole AUC and Cmax values. The AUC∞ and
AUClast of plasma isavuconazole in participants with mild,
moderate, or severe RI were not significantly different com-
pared with healthy participants with normal renal function.
The PK parameters of isavuconazole in plasma were similar
between healthy participants with normal renal function and
participants with mild, moderate, or severe RI.
Accurate assessment of kidney function is essential for de-
termining appropriate drug dosing regimens [20]. Therefore,
eGFR-MDRD equations have been developed to more accu-
rately assess renal function and renal impairment and appro-
priate drug dosage adjustments [20]. Historically, the CG
equation was the method most commonly used to assess drug
dosage adjustments in renally impaired patients in clinical
practice [20]. Currently, eGFR using the MDRD approach is
an alternative approach to the CG method to determine drug
dosages in patients with renal impairment [20–22]. However,
previous studies have shown discordance rates of up to 40%
and significant difference in drug dosing regimens between
theMDRD and CGmethods [21, 22].We found no significant
relationship between either total plasma isavuconazole Cmax
or total body clearance from plasma and renal function
assessed by CLcr (CG) or eGFR (MDRD). This is consistent
with a population PK study which showed that eGFR used as
a covariate did not have a significant effect on clearance of
isavuconazole [23]. These findings add further support that
dose adjustments of isavuconazole are unlikely to be required
Fig. 2 The relationship between
total clearance of isavuconazole
(CL) and renal function in relation
to creatinine clearance (CLcr) by
Cockcroft–Gault (CG) method
(a) and estimated glomerular
filtration rate (eGFR) by the
Modification of Diet in Renal
Disease (MDRD) method (b). CI
as confidence intervals
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in individuals with RI or in those with ESRD who are receiv-
ing hemodialysis.
Two approaches were used in the analysis of data: The first
approach examined renal function by categorically grouping
the severity of impairment (mild, moderate, severe or ESRD
as defined by CLcr by CG), and the second approach exam-
ined renal function as a continuous variable (eGFR or CLcr)
related to PK parameters to the measure of renal function.
Grouping by severity of renal impairment parallels the clinical
approach found in national and international guidelines and is
relevant to clinicians familiar with these guidelines [24–29].
The continuous variable approach was objective and indepen-
dent of empirical classification. Consistency between the two
approaches adds robustness to the findings of this study and
provides support to its conclusions.
In participants with ESRD, the decrease in AUC and Cmax
and wide variability for each when dialysis preceded drug
dosing were influenced by intercompartmental fluid shifts in-
trinsic to hemodialysis and post-dialysis recovery. The clear-
ance of drugs by conventional hemodialysis is predominantly
a passive diffusional process driven by unbound concentration
gradient between plasma water and dialysate [8, 30]. As the
binding of drug to plasma proteins increases, removal of drug
by dialysis will decrease [31]. Therefore, hemodialysis did not
clear isavuconazole from the plasma of individuals with
ESRD due to the high protein binding of isavuconazole
(>99.9%) predominantly to albumin. However, the longer
half-life and volume of distribution of isavuconazole in indi-
viduals with ESRD may also be due to decreased plasma
binding by albumin due to uremia which may impact drug
metabolism by the liver [32]. The increase in AUC in dialysis
patients may be due to the displacement of isavuconazole
from albumin by heparin while patients are on dialysis which
has been reported for some other drugs [33]. In view of the
low and intermittent dialytic clearance of isavuconazole from
plasma, it can be concluded that clearance of isavuconazole by
thrice weekly dialysis is unlikely to have any appreciable ef-
fects on the PK of isavuconazole in ESRD patients. Therefore,
post-dialysis supplementation of isavuconazole is unlikely to
be required. Conversely, if isavuconazole is inadvertently
overdosed, the overdose cannot be effectively managed by
hemodialysis.
Analysis of isavuconazole PK across renal function as a
continuous variable showed no significant impact of renal
function measured by eGFR on Cmax and AUC. Although
differences in the renal excretion of isavuconazole were ob-
served among groups with differing levels of renal impair-
ment, the overall level of renal excretion was quite small and
the observed differences would not be expected to impact on
the PK of isavuconazole in any significant way.
In this study, a single IV infusion of isavuconazole was
generally well tolerated by individuals with normal renal func-
tion; those with mild, moderate, or severe RI; and those with
ESRD. The number and percentage of participants experienc-
ing TEAEs were low and generally similar between groups,
and most TEAEs were considered mild. However, more indi-
viduals in the ESRD and severe RI groups experienced gas-
trointestinal disorders compared with those with normal renal
function. However, for those receiving hemodialysis, consid-
eration should be given to administering isavuconazole pre-
dialysis. Based on the findings of this study, dose adjustments
of isavuconazole are unlikely to be required in individuals
with RI or in those with ESRD who are receiving
hemodialysis.
Table 5 Summary of treatment-emergent adverse eventsa
Parameter n (%) Study part 1 Study part 2
Healthy control











TEAEs 7 (77.8) 7 (63.6) 4 (50.0) 5 (62.5) 5 (62.5) 4 (80.0)
Drug-related TEAEs 7 (77.8) 7 (63.6) 4 (50.0) 4 (50.0) 5 (62.5) 3 (60.0)
TEAEs leading to study discontinuation 1 (11.1)b 0 0 0 0 0
Most common TEAEsc
General disorders and administration site conditions 6 (66.7) 4 (36.4) 2 (25.0) 2 (25.0) 3 (37.5) 3 (60.0)
Nervous system disorders 3 (33.3) 4 (36.4) 2 (25.0) 2 (25.0) 4 (50.0) 1 (20.0)
Gastrointestinal disorders 0 3 (27.3) 1 (12.5) 1 (12.5) 2 (25.0) 2 (40.0)
Infections and infestations 0 2 (18.2) 0 0 0 1 (20.0)
Skin and subcutaneous tissue 0 2 (18.2) 1 (12.5) 0 0 0
ESRD end-stage renal disease, MedDRA medical dictionary for regulatory activities, RI renal impairment, TEAE treatment-emergent adverse event
a By MedDRAversion 12.1 system organ class
b TEAE was considered to be drug-related in this patient
c TEAEs occurring in ≥2 patients overall
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